Sign up
Pharma Capital

Theratechnologies rises as Europe certifies its Chinese manufacturing facilities

The pharmaceutical company is manufacturing an antiretroviral therapy for drug-resistant HIV patients
Trogarzo is an antiretroviral drug for patients with multidrug-resistant HIV-1 infection

Theratechnologies Inc (TSX:TH) (OTCMKTS:THERF), a specialty pharmaceutical company, announced Wednesday that the Chinese facility set to manufacture its HIV drug received the necessary certification from Europe.

Trogarzo is an antiretroviral drug used to treat patients with multidrug-resistant HIV-1 infection.

Shares of Montreal-based Theratechnologies closed up 9.3% to C$7.56 in Canada and advanced 9.8% to US$5.69 on the OTC Markets.

Manufacturing is set to take place at the Wuxi Biologics facilities in Wuxi City and Shanghai, both in China. The European Medicines Agency granted the facilities the Good Manufacturing Practice certificates required for pharmaceuticals to be sold in Europe.

“This is yet another important milestone towards the potential launch of Trogarzo in Europe,” said Luc Tanguay, president and CEO or Theratechnologies. More than ever, we are actively preparing for an approval in this territory to ensure that key markets will be receptive to this unique breakthrough treatment for patients with multidrug resistant HIV.”

Contact Angela Harmantas at [email protected]

Follow her on Twitter @AHarmantas


Register here to be notified of future TH Company articles
View full TH profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.